Literature DB >> 27093166

Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review.

Josephine Mauskopf1, Andrea V Margulis, Miny Samuel, Kathleen N Lohr.   

Abstract

BACKGROUND: Studies have explored the risk for and impact of respiratory syncytial virus (RSV) infection requiring hospitalization among healthy preterm infants born at 29-35 weeks of gestational age not given RSV immunoprophylaxis. We performed a systematic review and qualitative synthesis of these studies.
METHODS: Two experienced reviewers used prespecified inclusion/exclusion criteria to screen titles/abstracts and full-text studies using MEDLINE, Embase, BIOSIS and Cochrane Library (January 1, 1985, to November 6, 2014). We abstracted data on risk factors for RSV hospitalization, incidence and short- and long-term outcomes of RSV hospitalization. Using standard procedures, we assessed study risk of bias and graded strength of evidence (SOE).
RESULTS: We identified 4754 records and reviewed 27. Important risk factors for RSV hospitalization included young age during the RSV season, having school-age siblings and day-care attendance, with odds ratios >2.5 in at least one study (high SOE). Incidence rates for RSV hospitalizations ranged from 2.3% to 10% (low SOE). Length of hospital stays ranged from 3.8 to 6.1 days (low SOE). Recurrent wheezing rates ranged from 20.7% to 42.8% 1 to 2 years after RSV hospitalization (low SOE).
CONCLUSIONS: Young chronological age and some environmental risk factors are important clinical indicators of an increased risk of RSV hospitalization in healthy preterm infants 32 to 35 weeks of gestational age. SOE was low for estimates of incidence of RSV hospitalizations, in-hospital resource use and recurrent wheezing in this population. Studies were inconsistent in study characteristics, including weeks of gestational age, age during RSV season and control for confounding factors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27093166      PMCID: PMC4927309          DOI: 10.1097/INF.0000000000001163

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  56 in total

1.  Respiratory syncytial virus immunoprophylaxis: impact on epidemiology.

Authors:  N N Dougherty; H C Meissner
Journal:  Paediatr Drugs       Date:  2000 Mar-Apr       Impact factor: 3.022

2.  Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.

Authors:  T Heikkinen; H Valkonen; L Lehtonen; R Vainionpää; O Ruuskanen
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-01       Impact factor: 5.747

3.  Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis.

Authors:  Shawn L Ralston; Allan S Lieberthal; H Cody Meissner; Brian K Alverson; Jill E Baley; Anne M Gadomski; David W Johnson; Michael J Light; Nizar F Maraqa; Eneida A Mendonca; Kieran J Phelan; Joseph J Zorc; Danette Stanko-Lopp; Mark A Brown; Ian Nathanson; Elizabeth Rosenblum; Stephen Sayles; Sinsi Hernandez-Cancio
Journal:  Pediatrics       Date:  2014-11       Impact factor: 7.124

4.  Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons.

Authors:  X Carbonell-Estrany; J Quero
Journal:  Pediatr Infect Dis J       Date:  2001-09       Impact factor: 2.129

5.  Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany.

Authors:  Johannes G Liese; Eva Grill; Birgit Fischer; Irmgard Roeckl-Wiedmann; David Carr; Bernd H Belohradsky
Journal:  Eur J Pediatr       Date:  2003-03-01       Impact factor: 3.183

6.  Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.

Authors:  Steven Wegner; Julie Jacobson Vann; Gordon Liu; Patricia Byrns; Clement Cypra; William Campbell; Alan Stiles
Journal:  Pediatrics       Date:  2004-12       Impact factor: 7.124

7.  Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.

Authors:  Carmen Pedraz; Xavier Carbonell-Estrany; José Figueras-Aloy; José Quero
Journal:  Pediatr Infect Dis J       Date:  2003-09       Impact factor: 2.129

8.  The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.

Authors:  Barbara J Law; Joanne M Langley; Upton Allen; Bosco Paes; David S C Lee; Ian Mitchell; John Sampalis; Hervé Walti; Joan Robinson; Karel O'Brien; Carina Majaesic; Georges Caouette; Lyne Frenette; Nicole Le Saux; Brian Simmons; Sharon Moisiuk; Koravanagattu Sankaran; Cecil Ojah; Avash J Singh; Marc H Lebel; Godfrey S Bacheyie; Heather Onyett; Andrea Michaliszyn; Patricia Manzi; Diana Parison
Journal:  Pediatr Infect Dis J       Date:  2004-09       Impact factor: 2.129

9.  Clinical characteristics of respiratory syncytial virus infections in healthy versus previously compromised host.

Authors:  K Meert; S Heidemann; M Lieh-Lai; A P Sarnaik
Journal:  Pediatr Pulmonol       Date:  1989

10.  Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study.

Authors:  J-B Gouyon; J-C Rozé; C Guillermet-Fromentin; I Glorieux; L Adamon; M DI Maio; T Miloradovich; D Anghelescu; D Pinquier; B Escande; C Elleau
Journal:  Epidemiol Infect       Date:  2012-06-15       Impact factor: 4.434

View more
  17 in total

1.  Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.

Authors:  M Cetinkaya; T K Oral; S Karatekin; B Cebeci; A Babayigit; Y Yesil
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-04-08       Impact factor: 3.267

2.  Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation.

Authors:  Eric A F Simões; Evan J Anderson; Xionghua Wu; Christopher S Ambrose
Journal:  PLoS One       Date:  2016-11-29       Impact factor: 3.240

3.  Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series.

Authors:  Nienke M Scheltema; Angela Gentile; Florencia Lucion; D James Nokes; Patrick K Munywoki; Shabir A Madhi; Michelle J Groome; Cheryl Cohen; Jocelyn Moyes; Kentigern Thorburn; Somsak Thamthitiwat; Hitoshi Oshitani; Socorro P Lupisan; Aubree Gordon; José F Sánchez; Katherine L O'Brien; Bradford D Gessner; Agustinus Sutanto; Asuncion Mejias; Octavio Ramilo; Najwa Khuri-Bulos; Natasha Halasa; Fernanda de-Paris; Márcia Rosane Pires; Michael C Spaeder; Bosco A Paes; Eric A F Simões; Ting F Leung; Maria Tereza da Costa Oliveira; Carla Cecília de Freitas Lázaro Emediato; Quique Bassat; Warwick Butt; Hsin Chi; Uzma Bashir Aamir; Asad Ali; Marilla G Lucero; Rodrigo A Fasce; Olga Lopez; Barbara A Rath; Fernando P Polack; Jesse Papenburg; Srđan Roglić; Hisato Ito; Edward A Goka; Diederick E Grobbee; Harish Nair; Louis J Bont
Journal:  Lancet Glob Health       Date:  2017-10       Impact factor: 26.763

4.  Risk Factors for RSV Hospitalization in Healthy Preterm Infants: A Meta-analysis.

Authors:  Shaun Abeysinghe; Andrea V Margulis; Josephine Mauskopf; Claire Ainsworth
Journal:  Pediatr Infect Dis J       Date:  2017-07       Impact factor: 2.129

Review 5.  Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value.

Authors:  Natalia Olchanski; Ryan N Hansen; Elle Pope; Brittany D'Cruz; Jaime Fergie; Mitchell Goldstein; Leonard R Krilov; Kimmie K McLaurin; Barbara Nabrit-Stephens; Gerald Oster; Kenneth Schaecher; Fadia T Shaya; Peter J Neumann; Sean D Sullivan
Journal:  Open Forum Infect Dis       Date:  2018-02-07       Impact factor: 3.835

Review 6.  Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease.

Authors:  Josep Figueras-Aloy; Paolo Manzoni; Bosco Paes; Eric A F Simões; Louis Bont; Paul A Checchia; Brigitte Fauroux; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2016-09-14

7.  Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States.

Authors:  Rohan C Parikh; Kimmie K McLaurin; Andrea V Margulis; Josephine Mauskopf; Christopher S Ambrose; Melissa Pavilack; Sean D Candrilli
Journal:  Infect Dis Ther       Date:  2017-09-02

8.  Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan.

Authors:  Hsin Chi; Ching-Hu Chung; Yuh-Jyh Lin; Chyi-Her Lin
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

9.  Hospitalizations for viral respiratory infections in children under 2 years of age: epidemiology and in-hospital complications.

Authors:  Jessie N Zurita-Cruz; Alejandro Gutierrez-Gonzalez; Leticia Manuel-Apolinar; José Esteban Fernández-Gárate; María Luisa Arellano-Flores; Roberto Alejandro Correa Gonzalez; Guillermo Vázquez-Rosales; Rocio Sanchez-Armas; Nelly Cisneros-González
Journal:  BMC Pediatr       Date:  2020-06-09       Impact factor: 2.125

10.  The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.

Authors:  Amanda M Kong; Leonard R Krilov; Jaime Fergie; Mitchell Goldstein; David Diakun; Sally W Wade; Melissa Pavilack; Kimmie K McLaurin
Journal:  Am J Perinatol       Date:  2017-09-07       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.